It is worth mentioning that a Dot1L and menin combinatory inhibitors approach has been already proposed for therapy of some hematological malignancies including NPM1-mutant [60] and MLL-rearranged [61] leukemias. This evidence concerns the gene KMT2A and hematologic disorder.